CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares to cover over-allotments. Eleven’s common stock began trading on the NASDAQ Global Market under the ticker symbol “EBIO” on February 6, 2014.
Help employers find you! Check out all the jobs and post your resume.
